Baxter International Inc
NYSE:BAX
Intrinsic Value
Baxter International, Inc. engages in the provision of a portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, p... [ Read More ]
The intrinsic value of one
BAX
stock under the Base Case scenario is
66.2
USD.
Compared to the current market price of 40.4 USD,
Baxter International Inc
is
Undervalued by 39%.
Baxter International Inc's market capitalization is 20.5B USD.
BAX stock price is 40.4 USD.
BAX stock price (40.4 USD) is 39% less than its Intrinsic Value (66.2 USD).
BAX has upside potential of 14% compared to the average analyst price target.
Open Wall St Estimates
BAX's Revenue has dropped by 2% over the past 12 months.
BAX has positive Operating Income for the last twelve months.
BAX's Revenue is forecast to grow at a rate of 4% per year over the next 3 years.
BAX's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 3%.
BAX's Revenue has been growing by 8% per year for the last 3 years.
BAX has positive three-year average ROIC (Return on Invested Capital): 7%. The company is efficient at using invested capital to generate operating income.
BAX's D/E (Debt to Equity) is equal to 1.32.
BAX's ROIC (Return on Invested Capital) has decreased in the last 3 years from 11% to 3%.
BAX's long-term assets (28B USD) exceed its long-term liabilties (20B USD).
BAX's short-term assets (10B USD) exceed its short-term liabilties (7B USD).
BAX has positive Net Income for the last twelve months.
BAX has positive Free Cash Flow for the last twelve months.
BAX's Altman Z-Score is equal to 2.06.
BAX has a very low three-year average ROE (Return on Equity): 2%. The company is not efficient at transforming stockholders' equity into net income.
BAX's ROE (Return on Equity) has significantly increased in the last 3 years from 13% to 37%.
BAX's ROE (Return on Equity) for the past 12 months is very high and is equal to 37%.
BAX has positive Gross Profit for the last twelve months.
BAX has positive Net Debt. This means that the company has more debt (11B USD) than cash and short-term investments (3B USD).
BAX generates enough operating income (1B USD) to cover interest payments on its debt (484m USD).
Valuation Backtest
Baxter International Inc
Run backtest to discover the historical profit from buying and selling
BAX
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Baxter International Inc
Balance Sheet Decomposition
Baxter International Inc
| Current Assets | 9.6B |
| Cash & Short-Term Investments | 3.2B |
| Receivables | 2.7B |
| Other Current Assets | 3.7B |
| Non-Current Assets | 18.7B |
| PP&E | 5B |
| Intangibles | 12.6B |
| Other Non-Current Assets | 1.1B |
| Current Liabilities | 6.5B |
| Accounts Payable | 1.2B |
| Accrued Liabilities | 2.4B |
| Other Current Liabilities | 2.8B |
| Non-Current Liabilities | 13.4B |
| Long-Term Debt | 11.1B |
| Other Non-Current Liabilities | 2.2B |
Earnings Waterfall
Baxter International Inc
|
Revenue
|
14.8B
USD
|
|
Cost of Revenue
|
-9.5B
USD
|
|
Gross Profit
|
5.3B
USD
|
|
Operating Expenses
|
-4.1B
USD
|
|
Operating Income
|
1.3B
USD
|
|
Other Expenses
|
1.4B
USD
|
|
Net Income
|
2.7B
USD
|
Free Cash Flow Analysis
Baxter International Inc
What is Free Cash Flow?
BAX Profitability Score
Profitability Due Diligence
Baxter International Inc's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
Score
Baxter International Inc's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
BAX Solvency Score
Solvency Due Diligence
Baxter International Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Score
Baxter International Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BAX Price Targets Summary
Baxter International Inc
According to Wall Street analysts, the average 1-year price target for
BAX
is 45.9 USD
with a low forecast of 39.39 USD and a high forecast of 56.7 USD.
Ownership
BAX Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
BAX Price
Baxter International Inc
| Average Annual Return | -5.63% |
| Standard Deviation of Annual Returns | 24.5% |
| Max Drawdown | -65% |
| Market Capitalization | 20.5B USD |
| Shares Outstanding | 509 350 000 |
| Percentage of Shares Shorted | 1.96% |
Company Profile
Baxter International Inc
Country
Industry
Market Cap
Dividend Yield
Description
Baxter International, Inc. engages in the provision of a portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies, premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems and pharmacy automation, software, and services. The company is headquartered in Deerfield, Illinois and currently employs 60,000 full-time employees. The Company’s segments include Americas (North and South America), EMEA (Europe, Middle East and Africa) and APAC (Asia-Pacific), and Hillrom. The Americas, EMEA and APAC segments provide a portfolio of essential healthcare products, including acute and chronic dialysis therapies; sterile IV solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; and surgical hemostat and sealant products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space. The Company’s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices and by patients at home under physician supervision.
Contact
IPO
Employees
Officers
The intrinsic value of one
BAX
stock under the Base Case scenario is
66.2
USD.
Compared to the current market price of 40.4 USD,
Baxter International Inc
is
Undervalued by 39%.
You don't have any saved screeners yet
